Now processing ... 
 Now searching ... 
 Now loading ... 

機能性ディスペプシアの診療

米国の最新のガイドラインでは、年齢のcut-offを60歳に引き上げ60歳以上のすべての患者に上部消化管内視鏡を推奨している。しかし日本の胃癌の罹患率は米国よりも高く、適応には注意が必要である。
出典
imgimg
1: ACG and CAG Clinical Guideline: Management of Dyspepsia.
著者: Paul M Moayyedi, Brian E Lacy, Christopher N Andrews, Robert A Enns, Colin W Howden, Nimish Vakil
雑誌名: Am J Gastroenterol. 2017 Jul;112(7):988-1013. doi: 10.1038/ajg.2017.154. Epub 2017 Jun 20.
Abstract/Text: We have updated both the American College of Gastroenterology (ACG) and the Canadian Association of Gastroenterology (CAG) guidelines on dyspepsia in a joint ACG/CAG dyspepsia guideline. We suggest that patients ≥60 years of age presenting with dyspepsia are investigated with upper gastrointestinal endoscopy to exclude organic pathology. This is a conditional recommendation and patients at higher risk of malignancy (such as spending their childhood in a high risk gastric cancer country or having a positive family history) could be offered an endoscopy at a younger age. Alarm features should not automatically precipitate endoscopy in younger patients but this should be considered on a case-by-case basis. We recommend patients <60 years of age have a non-invasive test Helicobacter pylori and treatment if positive. Those that are negative or do not respond to this approach should be given a trial of proton pump inhibitor (PPI) therapy. If these are ineffective tricyclic antidepressants (TCA) or prokinetic therapies can be tried. Patients that have an endoscopy where no pathology is found are defined as having functional dyspepsia (FD). H. pylori eradication should be offered in these patients if they are infected. We recommend PPI, TCA and prokinetic therapy (in that order) in those that fail therapy or are H. pylori negative. We do not recommend routine upper gastrointestinal (GI) motility testing but it may be useful in selected patients.
Am J Gastroenterol. 2017 Jul;112(7):988-1013. doi: 10.1038/ajg.2017.15...

消化不良の鑑別診断

[ID0602]:消化不良の起因となる薬剤
Am Fam Physician. 2020 Jan 15;101(2):84-88.を参考に作製
出典
img
1: 著者提供

消化不良の起因となる薬剤

消化不良の原因となる薬剤と考えられている。投与量の減量または中止により消化不良が改善する可能性があり、高額な検査を避けられるかもしれない。
出典
imgimg
1: Evaluation and management of dyspepsia.
著者: O V Bazaldua, F D Schneider
雑誌名: Am Fam Physician. 1999 Oct 15;60(6):1773-84, 1787-8.
Abstract/Text: Dyspepsia, often defined as chronic or recurrent discomfort centered in the upper abdomen, can be caused by a variety of conditions. Common etiologies include peptic ulcers and gastroesophageal reflux. Serious causes, such as gastric and pancreatic cancers, are rare but must also be considered. Symptoms of possible causes often overlap, which can make initial diagnosis difficult. In many patients, a definite cause is never established. The initial evaluation of patients with dyspepsia includes a thorough history and physical examination, with special attention given to elements that suggest the presence of serious disease. Endoscopy should be performed promptly in patients who have "alarm symptoms" such as melena or anorexia. Optimal management remains controversial in young patients who do not have alarm symptoms. Although management should be individualized, a cost-effective initial approach is to test for Helicobacter pylori and treat the infection if the test is positive. If the H. pylori test is negative, empiric therapy with a gastric acid suppressant or prokinetic agent is recommended. If symptoms persist or recur after six to eight weeks of empiric therapy, endoscopy should be performed.
Am Fam Physician. 1999 Oct 15;60(6):1773-84, 1787-8.

上部消化管内視鏡検査が施行されていない消化不良を訴える患者に対するプロトンポンプ阻害薬(PPI)の効果

上部消化管内視鏡検査が施行されていない消化不良を訴える患者に対して、PPIは有意な効果が認められ、NNT=5であった。
出典
imgimg
1: American gastroenterological association technical review on the evaluation of dyspepsia.
Gastroenterology. 2005 Nov;129(5):1756-80. doi: 10.1053/j.gastro.2005.09.020.

警告症状のない45歳以下の消化不良患者の消化不良に対して、ピロリ菌のtest and treat戦略群とPPIによる経験的治療群の比較試験。

警告症状のない45歳以下の消化不良患者の消化不良に対して行われたイタリアの研究では、ピロリ菌のtest and treat戦略群(B群)が、オメプラゾール20mg/日による経験的治療群(A群)より、症状の軽減が有意に少ないことが示された。
出典
imgimg
1: Empirical prescribing for dyspepsia: randomised controlled trial of test and treat versus omeprazole treatment.
著者: Gianpiero Manes, Antonella Menchise, Claudio de Nucci, Antonio Balzano
雑誌名: BMJ. 2003 May 24;326(7399):1118. doi: 10.1136/bmj.326.7399.1118.
Abstract/Text: OBJECTIVE: To compare the efficacy of a "Helicobacter pylori test and treat" strategy with that of an empirical trial of omeprazole in the non-endoscopic management by empirical prescribing of young patients with dyspepsia.
DESIGN: Randomised controlled trial.
SETTING: Hospital gastroenterology unit.
PARTICIPANTS: 219 patients under 45 years old presenting with dyspepsia without alarm symptoms.
INTERVENTION: Patients received treatment with omeprazole 20 mg (group A) or with a urea breath test followed by an eradication treatment in case of H pylori infection or omeprazole alone in non-infected patients (group B). Lack of improvement or recurrence of symptoms prompted endoscopy.
MAIN OUTCOME MEASURES: Improvement in symptoms assessed by a dyspepsia severity score every two months; use of medical resources (endoscopic workload and medical consultation); clinical outcome.
RESULTS: 96/109 (88%) patients in group A and 61/110 (55%) in group B (P < 0.0001) had endoscopy: in 19 patients in group A and 32 in group B (20/67 infected and 12/43 non-infected) because of no improvement; in 77 further patients in group A and 29 in group B (7 infected and 22 non-infected) because of recurrence of symptoms during follow up. Endoscopy showed peptic ulcers only in group A; oesophagitis occurred significantly more often in group B than in group A. About 80% of examinations were normal in both groups, but nine duodenal scars occurred in group A.
CONCLUSIONS: Eradication treatment allows resolution of symptoms in a large number of patients with dyspepsia and reduces the endoscopic workload. After a trial of omeprazole, symptoms recur in nearly every patient. Such treatment is also likely to mask an appreciable number of peptic ulcers and cases of oesophagitis.
BMJ. 2003 May 24;326(7399):1118. doi: 10.1136/bmj.326.7399.1118.

消化不良に対するプロトンポンプ阻害薬(PPI)とH2受容体拮抗薬(H2RA)の比較。

消化不良に対する酸分泌促進薬の経験的投与において、PPIはH2RAより治療効果に優れる。
出典
imgimg
1: American gastroenterological association technical review on the evaluation of dyspepsia.
Gastroenterology. 2005 Nov;129(5):1756-80. doi: 10.1053/j.gastro.2005.09.020.

4週間のプロトンポンプ阻害薬投与後の尿路呼気試験の陽性率

ピロリ菌陽性患者にランソプラゾール30mg/日を4週間投与終了時に、33%で尿路呼気試験が陰性となった。治療終了後2週間ですべての患者が再度UBT陽性に戻った。このことからピロリ菌検査前にはPPIを2週間休薬することが必要と考えられている。
出典
imgimg
1: Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori.
著者: L Laine, R Estrada, M Trujillo, K Knigge, M B Fennerty
雑誌名: Ann Intern Med. 1998 Oct 1;129(7):547-50.
Abstract/Text: BACKGROUND: Proton-pump inhibitor therapy may cause false-negative results on Helicobacter pylori diagnostic testing.
OBJECTIVE: To determine the frequency and duration of conversion of urea breath test results from positive to negative in patients given a proton-pump inhibitor.
SETTING: Two urban university gastroenterology clinics.
PATIENTS: Patients infected with H. pylori who had positive results on urea breath tests.
INTERVENTION: Lansoprazole, 30 mg/d for 28 days.
MEASUREMENTS: The urea breath test was repeated at 28 days. If the results were negative, testing was repeated 3, 7, 14, and 28 days after completion of therapy until the results reverted to positive.
RESULTS: 31 (33%) of 93 patients in whom H. pylori was not eradicated had a negative breath test result while receiving lansoprazole. The proportions of patients whose breath test results were positive after completion of lansoprazole therapy were 91% (95% CI, 83% to 96%) at 3 days, 97% (CI, 90% to 99%) at 7 days, and 100% (CI, 96% to 100%) at 14 days.
CONCLUSION: Patients should not receive proton-pump inhibitors for 2 weeks before receiving the urea breath test for H. pylori infection.
Ann Intern Med. 1998 Oct 1;129(7):547-50.

ピロリ菌のtest and treat戦略を行う群と、早期に上部消化管内視鏡検査(GIF)を行う群の比較。

ピロリ菌のtest and treat戦略を行う群と、早期に上部消化管内視鏡検査(GIF)を行う群で、治療成績に差はない。
出典
imgimg
1: American gastroenterological association technical review on the evaluation of dyspepsia.
Gastroenterology. 2005 Nov;129(5):1756-80. doi: 10.1053/j.gastro.2005.09.020.

ピロリ菌のtest and treat戦略を行う群と、早期に上部消化管内視鏡(GIF)を行う群の最終的なGIFの施行数の比較。

ピロリ菌のtest and treat戦略を行う群で、有意にGIFの施行数が減少することが示された。
出典
imgimg
1: American gastroenterological association technical review on the evaluation of dyspepsia.
Gastroenterology. 2005 Nov;129(5):1756-80. doi: 10.1053/j.gastro.2005.09.020.

ピロリ菌罹患率とピロリ菌抗体検査の陽性予測値の関係

ピロリ菌抗体検査は、特にピロリ菌の罹患率の低い地域では、陽性予測値(検査が陽性の場合に、実際にピロリ菌に感染している可能性)が低く診断精度が低いため、推奨されない。
出典
imgimg
1: American College of Gastroenterology guideline on the management of Helicobacter pylori infection.
著者: William D Chey, Benjamin C Y Wong, Practice Parameters Committee of the American College of Gastroenterology
雑誌名: Am J Gastroenterol. 2007 Aug;102(8):1808-25. doi: 10.1111/j.1572-0241.2007.01393.x. Epub 2007 Jun 29.
Abstract/Text: Helicobacter pylori (H. pylori) remains a prevalent, worldwide, chronic infection. Though the prevalence of this infection appears to be decreasing in many parts of the world, H. pylori remains an important factor linked to the development of peptic ulcer disease, gastric malignanc and dyspeptic symptoms. Whether to test for H. pylori in patients with functional dyspepsia, gastroesophageal reflux disease (GERD), patients taking nonsteroidal antiinflammatory drugs, with iron deficiency anemia, or who are at greater risk of developing gastric cancer remains controversial. H. pylori can be diagnosed by endoscopic or nonendoscopic methods. A variety of factors including the need for endoscopy, pretest probability of infection, local availability, and an understanding of the performance characteristics and cost of the individual tests influences choice of evaluation in a given patient. Testing to prove eradication should be performed in patients who receive treatment of H. pylori for peptic ulcer disease, individuals with persistent dyspeptic symptoms despite the test-and-treat strategy, those with H. pylori-associated MALT lymphoma, and individuals who have undergone resection of early gastric cancer. Recent studies suggest that eradication rates achieved by first-line treatment with a proton pump inhibitor (PPI), clarithromycin, and amoxicillin have decreased to 70-85%, in part due to increasing clarithromycin resistance. Eradication rates may also be lower with 7 versus 14-day regimens. Bismuth-containing quadruple regimens for 7-14 days are another first-line treatment option. Sequential therapy for 10 days has shown promise in Europe but requires validation in North America. The most commonly used salvage regimen in patients with persistent H. pylori is bismuth quadruple therapy. Recent data suggest that a PPI, levofloxacin, and amoxicillin for 10 days is more effective and better tolerated than bismuth quadruple therapy for persistent H. pylori infection, though this needs to be validated in the United States.
Am J Gastroenterol. 2007 Aug;102(8):1808-25. doi: 10.1111/j.1572-0241....

消化不良患者の診療

[ID0702]:機能性ディスペプシア
60歳以上のEGD正常の患者は機能性ディスペプシアの治療を行う。
出典
imgimg
1: ACG and CAG Clinical Guideline: Management of Dyspepsia.
著者: Paul M Moayyedi, Brian E Lacy, Christopher N Andrews, Robert A Enns, Colin W Howden, Nimish Vakil
雑誌名: Am J Gastroenterol. 2017 Jul;112(7):988-1013. doi: 10.1038/ajg.2017.154. Epub 2017 Jun 20.
Abstract/Text: We have updated both the American College of Gastroenterology (ACG) and the Canadian Association of Gastroenterology (CAG) guidelines on dyspepsia in a joint ACG/CAG dyspepsia guideline. We suggest that patients ≥60 years of age presenting with dyspepsia are investigated with upper gastrointestinal endoscopy to exclude organic pathology. This is a conditional recommendation and patients at higher risk of malignancy (such as spending their childhood in a high risk gastric cancer country or having a positive family history) could be offered an endoscopy at a younger age. Alarm features should not automatically precipitate endoscopy in younger patients but this should be considered on a case-by-case basis. We recommend patients <60 years of age have a non-invasive test Helicobacter pylori and treatment if positive. Those that are negative or do not respond to this approach should be given a trial of proton pump inhibitor (PPI) therapy. If these are ineffective tricyclic antidepressants (TCA) or prokinetic therapies can be tried. Patients that have an endoscopy where no pathology is found are defined as having functional dyspepsia (FD). H. pylori eradication should be offered in these patients if they are infected. We recommend PPI, TCA and prokinetic therapy (in that order) in those that fail therapy or are H. pylori negative. We do not recommend routine upper gastrointestinal (GI) motility testing but it may be useful in selected patients.
Am J Gastroenterol. 2017 Jul;112(7):988-1013. doi: 10.1038/ajg.2017.15...

機能性ディスペプシアの診療

米国の最新のガイドラインでは、年齢のcut-offを60歳に引き上げ60歳以上のすべての患者に上部消化管内視鏡を推奨している。しかし日本の胃癌の罹患率は米国よりも高く、適応には注意が必要である。
出典
imgimg
1: ACG and CAG Clinical Guideline: Management of Dyspepsia.
著者: Paul M Moayyedi, Brian E Lacy, Christopher N Andrews, Robert A Enns, Colin W Howden, Nimish Vakil
雑誌名: Am J Gastroenterol. 2017 Jul;112(7):988-1013. doi: 10.1038/ajg.2017.154. Epub 2017 Jun 20.
Abstract/Text: We have updated both the American College of Gastroenterology (ACG) and the Canadian Association of Gastroenterology (CAG) guidelines on dyspepsia in a joint ACG/CAG dyspepsia guideline. We suggest that patients ≥60 years of age presenting with dyspepsia are investigated with upper gastrointestinal endoscopy to exclude organic pathology. This is a conditional recommendation and patients at higher risk of malignancy (such as spending their childhood in a high risk gastric cancer country or having a positive family history) could be offered an endoscopy at a younger age. Alarm features should not automatically precipitate endoscopy in younger patients but this should be considered on a case-by-case basis. We recommend patients <60 years of age have a non-invasive test Helicobacter pylori and treatment if positive. Those that are negative or do not respond to this approach should be given a trial of proton pump inhibitor (PPI) therapy. If these are ineffective tricyclic antidepressants (TCA) or prokinetic therapies can be tried. Patients that have an endoscopy where no pathology is found are defined as having functional dyspepsia (FD). H. pylori eradication should be offered in these patients if they are infected. We recommend PPI, TCA and prokinetic therapy (in that order) in those that fail therapy or are H. pylori negative. We do not recommend routine upper gastrointestinal (GI) motility testing but it may be useful in selected patients.
Am J Gastroenterol. 2017 Jul;112(7):988-1013. doi: 10.1038/ajg.2017.15...

消化不良の鑑別診断

[ID0602]:消化不良の起因となる薬剤
Am Fam Physician. 2020 Jan 15;101(2):84-88.を参考に作製
出典
img
1: 著者提供